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We previously reported that the apolipoprotein (apo) B48-carrying lipoproteins obtained from apoE knockout (𝑎𝑝𝑜𝐸
−/−) mice,
so called E
−/B48 lipoproteins, transformed mouse macrophages into foam cells and enhanced the phosphorylation of eukaryotic
translation initiation factor 2𝗼 (eIF-2𝗼). Furthermore, the eIF-2𝗼 phosphorylation inhibitor, 2-aminopurine (2-AP), attenuated
E
−/B48 lipoprotein-induced foam cell formation. The present report studied the effect of 2-AP on atherosclerosis in 𝑎𝑝𝑜𝐸
−/− mice.
Our results showed that the level of food intake, bodyweight, plasma cholesterol, and triglycerides was comparable in 𝑎𝑝𝑜𝐸
−/−
mice treated with or without 2-AP. However, the mean size of atherosclerotic lesions in the aorta sinus as well as the surface area
of the entire aorta of 2-AP-treated 𝑎𝑝𝑜𝐸
−/− mice were reduced by about 55% and 39%, respectively, compared to samples from
untreated control 𝑎𝑝𝑜𝐸
−/− mice. In addition, the 2-AP-treated 𝑎𝑝𝑜𝐸
−/− mice showed a significant decrease in glucose-regulated
protein 78 (GRP78) and phosphorylated eIF-2𝗼 in their aortic samples as compared to levels in untreated control 𝑎𝑝𝑜𝐸
−/− mice.
These observations suggest that endoplasmic reticulum stress is a causal mechanism for the development of atherosclerosis in
𝑎𝑝𝑜𝐸
−/− miceandthattherapeuticstrategiescanbedevelopedforusingeIF-2𝗼phosphorylationinhibitors,suchas2-AP,toprevent
or treat atherosclerosis.
1. Introduction
The endoplasmic reticulum (ER) fulfills multiple cellular
functions. Once ER functions are perturbed by various
pathological conditions, unfolded or misfolded proteins
accum ula teintheERl umen,r esul tin ginERstr esscha racter -
izedbyincreasingERmolecularchaperonesanddiminishing
global protein synthesis [1]. Activation of the signaling
networkinresponsetoERstressisknownasunfoldedprotein
response (UPR). There are three distinct UPR signaling
p a t h w a y st r i g g e r e di nr e s p o n s et oE Rs t r e s s ,w h i c ha r e
mediated by (1) RNA-dependent protein kinase-like endo-
plasmicreticulumkinase(PERK),(2)activatingtranscription
factor 6 (ATF6), and (3) inositol-requiring enzyme 1 (IRE1),
respectively, [2, 3]. Under physiological conditions, PERK,
ATF6, and IRE1 are associated with the abundant luminal
chaperone Bip (also known as glucose-regulated protein 78,
GRP78). This interaction keeps PERK, ATF6, and IRE1 in
a ni n a c t i v es t a t e .W h e nt h eE Ri so v e r l o a d e dw i t hn e w l y
synthesized proteins or is stimulated by agents that cause
unfolded proteins to accumulate, GRP78/Bip preferentially
associateswiththeunfoldedproteins,releasingPERK,ATF6,
and IRE1 to activate downstream signaling molecules. In the
PERK-mediated pathway, PERKs released from the GRP78
dimerize are autophosphorylated and manifest increased
catalytic activity. Activated PERK phosphorylates eIF-2𝗼.
The phosphorylated eIF-2𝗼 subsequently inhibits global pro-
tein synthesis, preventing further influx of nascent proteins2 ISRN Pharmacology
into an already saturated ER lumen. Paradoxically, eIF-2𝗼
phosphorylation enhances the translation of activating tran-
scription factor-4 (ATF4) and subsequently upregulates the
expression of ATF4-target genes, including several protein
chaperones[4].RecentstudiesalsodemonstratedthateIF-2𝗼
phosphorylation upregulates ATF6 expression and enhances
ATF6 activity and therefore increases the expression of its
target genes [5].
Although UPR signaling pathways are activated classi-
cally by unfolded ER proteins, increasing evidence demon-
strates that lipids/lipoproteins can also trigger UPR. For
instance, a prior study reported that accumulation of free
c h o l e s t e r o li nt h eE Rw a sa b l et oa c t i v a t eU P Rs i g n a l i n g
pathwaysinmouseperitonealmacrophages[6].Also,studies
from our laboratory demonstrated that treatment of mouse
macrophageswithlipoproteinscarryingapolipoprotein(apo)
B48 but lacking apoE (E
−/B48) induced foam cell forma-
tion, and enhanced phosphorylation of PERK and eIF-
2𝗼, increased expression of ATF4 and several molecular
chaperons and reduced global protein synthesis [7, 8]. Fur-
thermore, we observed that overexpression of dominant-
n e g a t i v em u t a n t so fP E R Ko re I F - 2 𝗼, or treatment with the
eIF-2𝗼 inhibitor, 2-aminopurine (2-AP), suppressed foam
cell formation induced by E
−/B48 lipoproteins [7, 8]. These
findings suggest that activation of the PERK-eIF2𝗼 signaling
pathway is an underlying mechanism by which E
−/B48
lipoproteins induce foam cell formation. Such a transforma-
t i o no fm a c r o p h a g e si n t oaf o a mc e l l si sa ne a r l ys t e po f
atherogenesis.
Individuals with defective isoforms of apoE, such as
apoE4, develop postprandial hypercholesterolemia and
atherosclerosis [9]. Similarly, apoE knockout (apoE
−/−)
mice manifest an elevated plasma cholesterol and develop
atherosclerosisinamannerthatresemblesthehumandisease
[10, 11]. The hypercholesterolemia in apoE
−/− mice results
mainly from the increased levels of E
−/B48 lipoproteins. It
is interesting to note that atherosclerotic lesions in the aorta
sinus of apoE
−/− mice show UPR, as reflected by increased
PERK phosphorylation in the lesions [12, 13]. Data from
the present report demonstrated that treatment of apoE
−/−
mice with the eIF-2𝗼 inhibitor 2-AP reduced atherosclerotic
lesions in their aortas compared to lesions observed in
control mice. Taken together, these findings suggest that
activation of eIF-2𝗼 signaling pathway is an underlying
mechanism for the development of atherosclerosis in
apoE
−/− mice and that inhibition of this UPR pathway might
provide a therapy strategy for treatment of atherosclerosis.
2. Materials and Methods
2.1. Animals and 2-AP Treatment. Male apoE
−/− mice were
obtained from Jackson Laboratory (Bar Harbor, ME). These
mice were generated using embryonic stem cells from the
1 2 9s t r a i no fm i c e[ 10] and were crossbred to C57BL/6 for
over 10 generations. They were maintained under barrier
conditions in a temperature-controlled environment and fed
with a mouse chow containing approximately 5% fat and
19% protein by weight (Harlan Teklad, Madison, WI). At 6
weeks of age, these mice were randomly assigned to one of
t w og r o u p s .O n eg r o u po ft h em i c ew a sg a v a g e - f e d2 - A Pa ta
dose of 200mg/kg body weight (BW) in 200𝜇Lw a t e ro n c e
every other day, and another group of mice was fed with
same volume of water as a control. Food intake and growth
were monitored by weighing the food and animals weekly.
After 24 weeks of treatment, mice were fasted overnight and
anesthetized with ketamine hydrochloride (80mg/kgBW)
and xylazine hydrochloride (16mg/kgBW). Approximately
0 . 5m Lo fb l o o dw a sc o l l e c t e df r o mt h ep o s t e r i o rv e n ac a v a
of each mouse. Thereafter, a 23-gauge needle was inserted
intotheleftventricleand4%paraformaldehydewasdelivered
intotheanimalatpressureof80mmHg.Asmallincisionwas
made into the liver to allow efflux of blood and fixative. After
fixation,theheartandtheproximalaortawereremovedfrom
the body and stored in 4% paraformaldehyde at 4
∘Cb e f o r e
sectioning.
2.2. Quantification of Atherosclerotic Lesions in the Mouse
Aorta. Th ea o r t aw a sc u ta tad i s t a n c eo f2 m mf r o mt h e
heart. The distal aorta (2mm from the heart to the iliac
bifurcation) was opened longitudinally using microscissors
and pinned flat on a black wax surface in a dissecting pan
under a dissecting microscope (SMZ1000, Nikon Instru-
ments Inc., Melville, NY), as described previously [11]. This
en face preparation was fixed overnight and stained with
Oil-Red-O. The photo-image of the aorta was captured with
a CoolSNAP digital camera (Nikon Instruments) mounted
on the SMZ1000 dissecting microscope. The atherosclerotic
lesion area and the total aortic area were measured using a
MetaMorph imaging system (Nikon Instruments).
The proximal aorta attached to the heart was used to
prepare cross-sections, as described previously [11]. Briefly,
the heart was sectioned transversely immediately below and
parallel to a plane formed by the line between atrial leaflets.
The lower portion of the heart was discarded. The portion
of the heart with the attached aorta was embedded either in
OCT or in paraffin, and sectioned from the attached aorta
towards the root of the aorta where the aorta valves were
attached. Sections (5–8𝜇m) were cut from the site where the
aorta valve cups appear at the aorta root. Every other section
was collected onto a set of microscope slides. The paraffin
sections were used for immunostaining as described below.
The frozen sections were stained with Oil-Red-O. The slides
were viewed using a microscope (E600, Nikon Instruments
Inc., Melville, NY) equipped with a Cool Snaps color dig-
ital camera and a MetaMorph computer image acquisition
system. The average area (𝜇m
2) and morphological features
(foam cell deposits, cholesterol clefts, lipid cores and fibrous-
caps) of the lesions in 16 sections were determined for each
mouse.
2.3. Immunohistochemical Staining. Immunostaining was
performed with the use of the VECTASTAIN ABC System
(VectorLaboratories,Inc.,Burlingame,CA).Theparaffinsec-
tions prepared as described above, was deparaffinized using
xylene.Theendogenousperoxidaseactivitywasblockedwith
5% hydrogen peroxide for 10min. After blocking with 5%ISRN Pharmacology 3
normal goat or rabbit serum, the sections were incubated
with primary antibodies against GRP78 or phosphorylated
eIF-2𝗼(A bcamInc.,Cambridge,MA).Aftertrea tmen twitha
secondary antibody produced from goats or rabbits, sections
were stained with diaminobenzidine or Nova red substrates
and counterstained with hematoxylin. The immunostaining
of the aortic sections were viewed using a microscope
equipped with an HQ2 CoolSNAP high-resolution camera
(Nikon) and the MegaMorth computer image acquisition
system. The images were viewed with a Nikon TE2000
fluorescence microscope.
2.4. Plasma Lipid Analysis. The levels of plasma choles-
terol and triglycerides were measured by spectrophotometric
quantification using reagents obtained from Sigma Chemical
C o .( S t .L o u i s ,M O ) .F o rm e a s u r i n gc h o l e s t e r o l ,t h em i x t u r e
of plasma and cholesterol-reaction reagent was incubated at
37
∘C for 30min, and the absorbance was read at 530nm with
a Dynex microplate reader (Thermo Labsystems, Franklin,
MA). For measuring triglycerides, the mixture of plasma
and triglyceride-reaction reagent was incubated at 37
∘Cf o r
10min, and the absorbance was read at 530nm. Plasma
concentrations of cholesterol and triglycerides were deter-
minedbasedontheabsorbanceobtainedbyincubationofthe
cholesterol and triglyceride standards provided by Sigma.
For determination of the cholesterol level in various
lipoproteins, a 100𝜇L plasma sample obtained from individ-
ual mice was fractionated using a fast performance liquid
chromatography (FPLC) (¨ Akta FPLC 900, Amersham Bio-
sciences, Piscataway, NJ) in a buffer containing 0.15M NaCl,
0.01M Na2HPO4,0 . 1 m ME D T A ,p H7 . 5 ,a tafl o wr a t eo f
0.5mL/min.Fortyfractions(0.5mL/fraction)werecollected.
It had already been established that fractions 14–17 contain
verylow-densitylipoprotein(VLDL)andchylomicrons,frac-
tions 18–25 contain LDL, and fractions 26–40 contain high-
density lipoprotein (HDL) [14, 15]. The cholesterol content in
variouslipoproteinswascalculatedfromtheconcentrationin
the FPLC fractions [14, 15].
2.5. Western Blot Analyses. The antibodies against phos-
phorylated eIF-2𝗼, GRP78 and lysosomal acid lipase (LAL)
were obtained from Abcam Inc. (Cambridge, MA), while the
antibodies against eIF-2𝗼 and 𝗽-actin were obtained from
SantaCruzBiotechnologyInc.(SantaCruz,CA).Aortasfrom
t w om i c ew e r ep o o l e d ,h o m o g e n i z e di n2 0m MT r i s - C la n d
centrifuged at 14,000rpm for 10min at 4
∘C. Supernatants
containing 15𝜇g protein were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis on 10% gels and
transferred to polyvinylidene difluoride membranes. Mem-
branes were blocked with 5% fat-free milk in TBS-T (2.5mM
Tris, 15mM NaCl, 0.01% Tween 20; pH 7.6) and then conse-
quently incubated with primary antibodies against indicated
proteins and horseradish peroxidase-conjugated secondary
antibodies, as previously described [16]. Immunoreactive
bands were visualized using ECL-plus chemiluminescence
reagent(GEHealthcareHealthcare-Amersham)andanalyzed
with a GS-700 Imaging Densitometer (Bio-Rad, Hercules,
CA).
Table 1: Mouse body weights and plasma lipids.
Body weight
(g)
Food intake
(g/g BW/day)
Plasma
cholesterol
(mg/dL)
Plasma
triglycerides
(mg/dL)
Control 27.8 ± 0.5 0.25 ± 0.07 513 ± 29 146 ± 18
2-AP 26.9 ± 0.9 0.24 ± 0.03 530 ± 39 147 ± 17
Male apoE
−/− mice at 6 weeks of age were gavage-fed 200𝜇lw a t e r( c o n t r o l )
or 200mg/kg BW of 2-AP once every other day for 24 weeks. Body weight
and food intake were monitored by weighing the animals and food weekly.
Data presented are the final body weights at the end of the experiment and
the average of food intake over 24 weeks. Bloodsamples were obtained from
apoE
−/− mice gavage-fed with 2-AP or water alone (control). Plasma total
triglycerides and total cholesterolwere determined as described in Materials
and Methods. Values represent the mean SEM of 12 mice.
2.6. Statistical Analysis. The data are reported as mean ±
standard error of the mean. The differences between 2-AP
treatment and control groups were analyzed by Student’s 𝑡-
test. Differences were considered significant at a 𝑃 value less
than 0.05.
3. Results
3.1. Effect of 2-AP on Body Weight and Food Intake. The
pharmacological properties of 2-AP, such as effective dose 50
(ED50) and effective half-life (𝑡1/2), have not been tested in
vivo. The Material Safety Data Sheet produced by InvivoGen
(San Diego, CA) indicates that the lethal dose 50 (LD50) of
2-AP via oral administration and intraperitoneal injection of
rats is 723 and 270mg/kg body weight (BW), respectively.
A preliminary study in our laboratory demonstrated that
gavage feeding of 2-AP to apoE
−/− mice at doses greater than
400mg/kgBWonceeveryotherdayreducedfoodintakeand
resulted in death (data not show). In the present study, we
observed that feeding 2-AP at a dose of 200mg/kgBW once
every other day did not reduce food intake and body weight,
and did not increase mortality within 24 weeks as compared
to untreated control apoE
−/− mice (Table 1). Specifically, the
average of food intake of apoE
−/− mice at 24–30 weeks of
age with or without 2-AP treatment was 0.24 ± 0.03 and
0.25±0.07gchow/gBW/ day ,respectively .Thebodyweightof
t h e s em i c ea t3 0w e e k so fa g ew a sa b o u t2 7g .N os i g n i fi c a n t
difference was observed between the 2-AP treated and the
untreated control mice.
3.2. 2-AP Reduces Atherosclerosis but Does Not Affect Plasma
Lipids in ApoE
−/− Mice. We previously reported that 2-
AP inhibited E
−/B48 lipoprotein-induced transformation of
macrophagesintofoamcells.Thepresentstudyexaminedthe
effect of 2-AP on atherosclerosis in apoE
−/− mice. Figures
1(a) and 1(b) show examples of cross-sections and en face
preparations of aortas obtained from apoE
−/− mice treated
with or without 2-AP. Data in Figures 1(c) and 1(d) show that
the mean size of atheroscleroticlesions in the aorta sinus and
t h es u r f a c ea r e ao ft h ee n t i r ea o r t ao f2 - A P - t r e a t e da p o E
−/−
mice were reduced by about 55% and 39%, respectively,
compared to those in the untreated control apoE
−/− mice.4 ISRN Pharmacology
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Figure1:Theeffectof2-APonatherosclerosis.MaleapoE
−/− miceat6weeksofageweregavage-fed 200𝜇Lwa ter(co n tr ol)o r200mg/kgB W
of 2-AP once every other day for 24 weeks. Heart-aorta samples were collected. (a) Frozen sections were cut from the mouse aortic sinus and
stainedwithOil-Red-O.Magnification=100.(b)Theaveragearea(𝜇m
2)ofthelesionsinsectionswasdeterminedinmicegiven2-APorwater
as a vehicle control. (c) Aortas from the aortic root to the iliac bifurcation were collected and opened longitudinally. The en face preparations
werefixedandstainedwithOil-Red-O.Magnification+0.5x.(d)Theatheroscleroticlesionareaandthetotalaorticareaweremeasured.Data
are expressed as the percentage of the aortic surface area covered by atherosclerotic lesions, after determining the atherosclerotic lesion area
and the total aortic area. Values are the mean ± SEM of 12 mice.
∗𝑃 < 0.05 as compared to untreated control mice.
Consistent with the smaller lesion size, the advanced lesions
were reduced markedly in 2-AP-treated mice. For instance,
the number of lipid cores (acellular areas) in the aortic sinus
inthe2-AP-treatedanduntreatedcontrolapoE
−/− mice were
1.2 ± 0.6 and 0.4 ± 0.1/section (𝑃 < 0.05), respectively. These
results,togetherwithourpreviousfindingsthat2-APinhibits
E
−/B48 lipoprotein-induced foam cell formation [7], suggest
that 2-AP is able to inhibit atherogenesis in vitro and in vivo.
An increase in plasma cholesterol and triglycerides has
been suggested to be a risk factor for atherosclerosis [17]. To
determine whether the reduction in atherosclerotic lesions
induced by 2-AP treatment was due to a change in plasma
cholesterol and triglycerides, we measured the levels of
plasma cholesterol and triglycerides in apoE
−/− mice with
or without 2-AP treatment. As the data in Table 1 show
that the average plasma concentrations of total cholesterol
and triglycerides were 513 and 146, respectively, in apoE
−/−
mice without 2-AP treatment and that 2-AP treatment did
not significantly alter these plasma lipid levels. To inves-
tigate whether 2-AP feeding affected the distribution ofISRN Pharmacology 5
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Figure 2: Distribution of cholesterol among plasma lipoprotein fractions. Plasma obtained from 2-AP-treated apoE
−/− mice and untreated
control mice was fractionated with a FPLC system. (a) Representative FPLC cholesterol profiles for each group of mice. (b) Cholesterol levels
in plasma lipoprotein fractions obtained from control and 2-AP treated apoE
−/− mice.
cholesterol among the lipoproteins, we fractionated mouse
plasma with an FPLC system (Figure 2(a)). As the data in
Figure 2(b)show,theplasmacholesterollevelsinVLDL,LDL,
a n dH D Lf r a c t i o n sw e r ec o m p a r a b l ei n2 - A P - t r e a t e da n d
untreatedcontrolmice.Theseresultssuggestthatthereduced
atherosclerotic lesions in 2-AP treated mice were not due to
altered levels of plasma lipids.
3.3. 2-AP Reduces ER Stress in the Aortas of ApoE
−/− Mice.
We previously reported that transformation of macrophages
into foam cells by E
−/B48 lipoproteins was associated with
ER stress, as reflected by increased phosphorylation of PERK
and eIF-2𝗼. Further that 2-AP inhibited E
−/B48 lipoprotein-
induced foam cell formation and reduced PERK and eIF-2𝗼
phosphorylation. The present report studied the effect of 2-
AP on the expression level of total and phosphorylated eIF-
2𝗼intheaortaofapoE
−/− mice.DatainFigure 3(a)showthat
the level of total eIF-2𝗼 was comparable in aortas obtained
from apoE
−/− mice treated with or without 2-AP treatment.
In contrast, the level of phosphorylated eIF-2𝗼 in the aorta
was about 64% lower in 2-AP-treated apoE
−/− mice than in
untreated control mice (Figure 3(b)). The data in Figure 3(c)
demonstrate that the protein level of chaperon GRP78 was
reduced by ∼53% in 2-AP-treated apoE
−/− mice as compared
to the untreated control littermates.
Wepreviouslyreportedthatintralysosomalaccumulation
of lipids/lipoproteins induced by E
−/B48 lipoproteins was
associated with decreased lysosomal hydrolase LAL, and
that 2-AP treatment restored E
−/B48 lipoprotein-reduced
expression of LAL. Therefore, the present report compared
the protein levels of LAL in the aorta of apoE
−/− mice with or
without 2-AP treatment. Data in Figures 3(a) and 3(c) show
that the protein level of aortic LAL was ∼2 . 6f o l dh i g h e ri n2 -
AP-treated apoE
−/− mice than in their untreated littermates.
Having demonstrated the inhibitory activity of 2-AP on
ER stress in the aorta, we then compared the expression of
GRP78 and phosphorylated eIF-2𝗼 in the lesional area in the
aorta sinus. As the representative immunostaining sections
in Figure 4 show, the atherosclerotic lesions, especially the
areas close to the plaque surface, accumulated cells positively
stained by antibodies against GRP78 or phosphorylated eIF-
2𝗼.Th en u m b e ro fp o s i t i v e l ys t a i n e dc e l l si n2 - A P - t r e a t e d
apoE
−/− mice was much less than those in untreated control
mice. These results are consistent with the Western blot data
showninFigure 3(a).Thesefindingsprovideevidencethat2-
AP inhibits ER stress in the aorta of apoE
−/− mice.
4. Discussion
The most important finding of this report is that oral feed-
ing of the eIF-2𝗼 phosphorylation inhibitor 2-AP reduced
atherosclerotic lesions in apoE
−/− mice. This finding suggests
that induction of eIF-2𝗼 phosphorylation is a causal mecha-
nism for the development of atherosclerosis in apoE
−/− mice.
Four eIF-2𝗼 k i n a s e sh a v eb e e ni d e n t i fi e di nm a m m a l i a n
cells,whicheachcatalyzeeIF-2𝗼phosphorylationinresponse
to various stressful cellular events [18, 19]. Specifically, ER
stress activates PERK, heme deprivation activates heme-
regulated inhibitor (HRI), virus infection activates double-
stranded RNA-activated protein kinase (PKR) and amino
acid deprivation activates general control nonderepressible-2
(GCN2) [19]. Previous studies from our laboratory demon-
strated that treatment of mouse macrophages with E
−/B48
lipoproteins induced phosphorylation of PERK but no other6 ISRN Pharmacology
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Figure 3: The effect of 2-AP on protein expression in the aorta. Distal regions of aortas from control and 2-AP treated apoE
−/− mice were
minced and homogenized. Protein levels in the aorta extract were determined with western blot analysis using antibodies against eIF-2𝗼 and
phosphorylated eIF-2𝗼 (p-eIF2𝗼), GRP78, LAL (liposomal acid lipase), and 𝗽-actin. The level of p-eIF2𝗼 was expressed relative to the eIF-2𝗼
immunoblot intensity. The levels of the other proteins were expressed relative to 𝗽-actin. Data are expressed as the mean ± SEM of three
independent experiments.
∗𝑃 < 0.05 as compared to untreated control mice.
eIF-2𝗼 kinases and that overexpression of a nonphosphory-
latable PERK mutantattenuated E
−/B48 lipoprotein-induced
eIF-2𝗼phosphorylationandfoamcellformation[7,8].These
findings suggest that PERK is responsible for the increased
eIF-2𝗼 phosphorylation observed in E
−/B48 lipoprotein-
treated macrophages. A high plasma level of E
−/B48 lipopro-
t e i n si sah a l l m a r kf e a t u r eo fapoE
−/− mice [10, 20]. Data
from the present report demonstrated that 2-AP treatment
reducedeIF-2𝗼phosphorylationintheaortaapoE
−/− mice.It
is highly likely that plasma E
−/B48 lipoproteins infiltrate into
the arterial walls of apoE
−/− mice, where they activate PERK
andsequentiallyincreaseeIF-2𝗼phosphorylationinvascular
cells, including resident macrophages.
AconsequenceofeIF-2𝗼phosphorylationisupregulation
of protein chaperons [19]. Indeed, phosphorylation of eIF-
2𝗼 induced by E
−/B48 lipoproteins has been associated
with increased expression of calreticulin and GRP 78 [7].
InhibitionofeIF-2𝗼byanonphosphorylatableeIF-2𝗼mutant
or an 2-AP attenuated E
−/B48 lipoprotein-induced expres-
sion of these protein chaperons [7]. Data from the present
reportshowedthat2-APtreatmentreducedtheexpressionof
GRP78.ISRN Pharmacology 7
p-eIF-2𝗼
GRP78
Control 2-AP
50 𝜇m
Figure 4: Representative immunochemical staining sections of
aorta sinus. The heart-aorta samples were collected from apoE
−/−
mice fed 2-AP or equal volume of water (control). Paraffin sections
were cut from the aorta sinus and immunostained with antibodies
against p-eIF-2𝗼 or GRP78. Magnification = 200x.
Red uctioninglobalp r oteinsyn thesisisanotherhallmark
consequence of eIF-2𝗼 phosphorylation [4]. Under physio-
logical conditions, inhibition of global protein synthesis and
upregulationofproteinchaperonesreducestheaccumulation
of newly synthesized proteinsin the ER, thereby relieving ER
stress [21, 22]. However, constant phosphorylation of eIF-2𝗼
and inhibition of global protein synthesis might overpower
normal cellular functions, causing pathological conditions
[21, 22]. For example, we previously observed that E
−/B48
lipoprotein-induced eIF-2𝗼 phosphorylation was associated
withreducedglobalproteinsynthesisandreducedexpression
of lysosomal hydrolases, such as lysosomal acid lipase (LAL)
[23]. In addition, we previously observed that inhibition
of eIF-2𝗼 phosphorylation by 2-AP, or a nonphosphorylat-
able eIF-2𝗼 mutant, attenuated the reduced expression of
L A La n di n h i b i t e df o a mc e l lf o r m a t i o ni n d u c e db yE
−/B48
lipoproteins [7, 8]. LAL is the sole hydrolase responsible for
cleavage of cholesteryl esters delivered to lysosomes [24, 25].
Taken together, our previous studies suggest that reduction
in lysosomal hydrolases could be a fundamental mech-
anism by which E
−/B48 lipoproteins trigger intracellular
lipid/lipoprotein accumulation and transform macrophages
into foam cells [23]. Correspondingly, the present report
demonstrated that treatment of apoE
−/− mice with 2-AP
significantly elevated the protein level of LAL in the apoE
−/−
mouse aorta. It is possible that the E
−/B48 lipoproteins
depositedinthearterialwallinduceeIF-2𝗼phosphorylation,
which downregulates lysosomal hydrolases, such as LAL,
in the resident macrophages, and therefore reduces the
degradationofE
−/B48lipoproteinsleadingtointralysosomal
E
−/B48 lipoprotein accumulation and resulting in foam cell
formation and atherosclerosis development. This postulation
is supported by the evidence showing that patients with a
deficiency of LAL manifest both an accumulation of lipids
in cells and develop premature atherosclerosis [25]. Further
more, overexpression of LAL reduces atherosclerotic lesions
in mice deficient in low-density lipoprotein receptor [26].
5. Conclusion
ThisreportdemonstratedthatERstressoccurredintheaorta
of apoE
−/− mice, as reflected by increased phosphorylation
of PERK and eIF-2𝗼 and by increased expression of chap-
eron GRP78. We also observed that inhibition of eIF-2𝗼
phosphorylation by 2-AP reduced atherosclerotic lesions in
the aorta of apoE
−/− mice. These observations suggest that
induction of ER stress, that is, activation of the PERK-eIF2𝗼
signaling cascade, is a causal mechanism for development of
atherosclerosis in apoE
−/− mice. Such insights will inform
novel strategies for using ER stress inhibitors such as 2-AP
to prevent or treat atherosclerosis.
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